In this article, we will list the 5 Best Multibagger Penny Stocks to Invest In. Please visit 10 Best Multibagger Penny Stocks to Invest In if you would like to see the extended list and the methodology behind it.
5. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
Share Price: $4.30
Stock Upside Potential: 198.67%
Number of Hedge Fund Holders: 32
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best multibagger penny stocks to invest in. On March 25, Cantor Fitzgerald reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $19 price target.
The positive stance is in response to the company making significant progress on the development of TSHA-102, an investigational gene transfer therapy in evaluation for Rett syndrome. Chief Executive Officer Sean Noland has already confirmed they are bolstering commercial-readiness efforts ahead of potential registration.
Photo by George Morina on Pexels
Taysha Gene Therapies has also received FDA clearance to initiate the ASPIRE trial in 3 patients to support a potential broad label in the second quarter. The milestone follows a favorable tolerability profile, continued patient enrollment, and a well-defined regulatory trajectory.
Amid TSHA-102 development progress, Taysha Gene Therapies reported a net loss of $109 million, or $0.34 per share, for the year ended December 31, 2025. It was a significant increase from a net loss of $89.3 million, or $0.36 a share, for the year ended 2024. The wider-than-expected net loss was due to an increase in research and development expenses, which came in at $86.4 million, up from $66 million in 2024.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic central nervous system diseases. Their lead candidate, TSHA-102, uses miRNA-regulatory technology to treat Rett syndrome, aiming to address the disease’s underlying genetic cause.
4. CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Share Price: $4.56
Stock Upside Potential: 217.65%
Number of Hedge Fund Holders: 33
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best multibagger penny stocks to invest in. On March 23, analysts at Piper Sandler reiterated an Overweight rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and increased the price target to $12 from $10.
The price target hike comes against the backdrop of topline Phase 1 data on varsetatug maseatecan in third-line and later metastatic colorectal cancer. Clinical trial results showed that the candidate drug achieved a 32% objective response rate and an 84% disease control rate.
The positive Phase 1 data reinforce Varseta-M’s potential as a standard of care for the treatment of colorectal cancer. CytomX is to engage the FDA to discuss the initial registration path for bringing this highly innovative, first-in-class ADC to the market.
The company has also initiated a Phase Ib study of Varseta-M combined with Avastin, as it also plans to start a Phase Ib/II trial that combines Avastin with chemotherapy in earlier-line colorectal cancer.
CytomX Therapeutics also plans to present Phase I data on CX-801 combined with KEYTRUDA in advanced melanoma patients by the end of the year. It has priced a $250 million public offering of its common stock at $5.30. The company plans to use the net proceeds from the offering to accelerate its drug development efforts.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics, which are masked, conditionally activated antibody treatments designed to target tumor microenvironments. This technology aims to improve cancer treatment safety and efficacy by localizing drug activity within tumors, reducing toxicity in healthy tissues.
3. AtaiBeckley Inc. (NASDAQ:ATAI)
Share Price: $3.70
Stock Upside Potential: 319.45%
Number of Hedge Fund Holders: 23
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated coverage of AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $12 price target.
The Buy rating underlines the investment bank’s confidence in the company’s long-term prospects as a leader in the emerging field of psychedelic medicine. BPL-003 and VLS-01 are Atai Life Sciences candidate drugs in the treatment of mental health conditions under development to address resistant depression.
Deutsche Bank expects the program to leverage Spravato’s commercial model to address resistant depression. The bank is also confident that psychedelic therapies will go mainstream in the next few years. The optimism comes amid expectations that Atai will deliver top-line Phase 2 data for VLS-01 in the second half of the year. The company is also expected to deliver Phase 2a Part 4 data for BPL-003 in the fourth quarter.
AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, particularly using psychedelic compounds and other psychoactive drugs. Founded in 2018, the company aims to heal mental health conditions like depression, anxiety, and addiction through a portfolio of therapeutic candidates.
2. Rezolve AI Plc. (NASDAQ:RZLV)
Share Price: $3.13
Stock Upside Potential: 337.34%
Number of Hedge Fund Holders: 18
Rezolve AI Plc. (NASDAQ:RZLV) is one of the best multibagger penny stocks to invest in. On March 31, H.C. Wainwright reiterated a Buy rating on Rezolve AI Ltd. (NASDAQ:RZLV) with a $12 price target, impressed by the company’s 2025 financial results, which exceeded market expectations.
The company delivered record revenue of $46.8 million, up from essentially zero sales in 2024. Following the significant sales increase, the company has raised its 2026 revenue guidance to $360 million from $350 million. The robust revenue increase would come as the company has more than 950 million enterprise customers and reached 112.7 billion API calls in 2025.
In addition, Rezolve AI Ltd. entered 2026 in its strongest-ever capital position, with current cash reserves providing more than sufficient runway for all day-to-day operations and organic growth. The company does not have any plans to raise equity for operational needs. However, it is open to using equity to conduct high-value, profitable acquisitions that will generate self-financing revenue.
Rezolve AI Plc. (NASDAQ:RZLV) is a technology company that provides AI-powered solutions for the retail and e-commerce sectors, designed to enhance customer engagement, increase revenue, and streamline transactions. It focuses on “conversational commerce” and “agentic commerce,” allowing retailers to engage customers with human-like interactions across multiple channels.
1. Rumble Inc. (NASDAQ:RUM)
Share Price: $4.72
Stock Upside Potential: 369.09%
Number of Hedge Fund Holders: 20
Rumble Inc. (NASDAQ:RUM) is one of the best multibagger penny stocks to invest in. On March 23 at the 38th Annual Roth Conference, Rumble Inc. (NASDAQ:RUM) showcased its ambitious transformation into an advertising and AI cloud infrastructure company.
The transformation from a free speech video platform has resulted in the company’s monthly active users surging from 1 million in 2020 to 52 million, helping bolster its advertising business. On the other hand, the planned acquisition of Northern Data is poised to enhance the company’s AI cloud capabilities. Rumble also plans to enhance its AI-powered Applications for small to medium-sized businesses.
In addition to pursuing AI cloud opportunities, Rumble has set its sights on taking on the likes of YouTube in advertising. It has already signed a $100 million advertising deal with Tether, split over two years. It also plans to expand government relationships globally, including in El Salvador, to pursue growth opportunities. The company is also targeting Positive EBITDA over the next two years, driven by strategic capital deployment.
Rumble Inc. (NASDAQ:RUM) is a video-sharing platform and cloud services provider that operates primarily as an alternative to mainstream platforms like YouTube, focusing on a “cancel culture-free” environment. The company operates two main business segments: Rumble Services and Rumble Cloud.
While we acknowledge the potential of RUM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RUM and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
